Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.47 |
| ▸ | FAP | Q12884 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899419 | 0.88 | DPP4 (0.45) | DPP4KDM4D | |
| SCHEMBL7975438 | 0.87 | DPP4 (0.47) | DPP4FAPCYP3A4CYP2D6CYP1A2 | |
| SCHEMBL3899886 | 0.87 | DPP4 (0.47) | DPP4FAP | |
| SCHEMBL3905904 | 0.86 | DPP4 (0.45) | DPP4JAK3BTK | |
| SCHEMBL3897385 | 0.86 | DPP4 (0.44) | DPP4JAK3BTK | |
| SCHEMBL3898788 | 0.86 | DPP4 (0.44) | DPP4FAPKDM4DJAK3BTK | |
| SCHEMBL13647359 | 0.85 | DPP4 (0.57) | DPP4FAPCYP3A4CYP2D6KDM4D | |
| SCHEMBL13647447 | 0.85 | DPP4 (0.45) | DPP4 | |
| SCHEMBL12906374 | 0.85 | DPP4 (0.46) | DPP4FAPKDM4DJAK3BTK | |
| SCHEMBL13647462 | 0.85 | DPP4 (0.45) | DPP4FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009433-A1 | BICYCLIC PYRROLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009433-A1 | BICYCLIC PYRROLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2264034-A1 | BICYCLIC PYRROLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009433-A1 | BICYCLIC PYRROLE COMPOUND | HPD, DPYD, PPIP5K2 | DPP4 907/4885FAP 1057/4885CYP3A4 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.